- Home
- IMMP vs NGS Comparison
IMMP vs NGS Comparison
Compare IMMP & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- NGS
- Stock Information
- Founded
- IMMP 1987
- NGS 1998
- Country
- IMMP Australia
- NGS United States
- Employees
- IMMP N/A
- NGS N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- NGS Oilfield Services/Equipment
- Sector
- IMMP Health Care
- NGS Energy
- Exchange
- IMMP Nasdaq
- NGS Nasdaq
- Market Cap
- IMMP 211.1M
- NGS N/A
- IPO Year
- IMMP N/A
- NGS 2002
- Fundamental
- Price
- IMMP $1.86
- NGS $20.11
- Analyst Decision
- IMMP Buy
- NGS Strong Buy
- Analyst Count
- IMMP 2
- NGS 1
- Target Price
- IMMP $8.50
- NGS $32.00
- AVG Volume (30 Days)
- IMMP 648.0K
- NGS 71.1K
- Earning Date
- IMMP 05-16-2025
- NGS 05-12-2025
- Dividend Yield
- IMMP N/A
- NGS N/A
- EPS Growth
- IMMP N/A
- NGS 260.53
- EPS
- IMMP N/A
- NGS 1.37
- Revenue
- IMMP $3,019,249.00
- NGS $156,742,000.00
- Revenue This Year
- IMMP $11.25
- NGS $12.87
- Revenue Next Year
- IMMP $10.22
- NGS $15.40
- P/E Ratio
- IMMP N/A
- NGS $14.68
- Revenue Growth
- IMMP 24.11
- NGS 29.36
- 52 Week Low
- IMMP $1.32
- NGS $16.70
- 52 Week High
- IMMP $3.34
- NGS $29.74
- Technical
- Relative Strength Index (RSI)
- IMMP 53.43
- NGS 53.74
- Support Level
- IMMP $1.44
- NGS $17.63
- Resistance Level
- IMMP $2.71
- NGS $19.68
- Average True Range (ATR)
- IMMP 0.17
- NGS 1.00
- MACD
- IMMP 0.05
- NGS 0.28
- Stochastic Oscillator
- IMMP 29.75
- NGS 90.51
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.